Skip to Content

Promising results with neoadjuvant atezolizumab for stage IB-IIIB NSCLC

Neoadjuvant atezolizumab resulted in a pathological response (MPR) in 21% of patients with resectable stage IB-IIIB NSCLC and significantly improvement in surgical outcomes with a high degree of R0 resection of 91% according to data from the primary analysis of the phase II study Cancer Mutation Consortium (LCMC) 3.

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Back to top